Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

NCT07028853 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07028853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07028853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Recruiting
Start date
September 28, 2025
Completion date
December 8, 2034
Enrollment
1,000 (estimated)
Sites
319

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate, hormone sensitive prostate cancer, metastatic castration sensitive prostate cancer (mcspc), prostate cancer